Obesity, insulin resistance and breast cancer outcomes

Breast

Volumn 24, Issue , 2015, Pages S56-S59

  Goodwin, Pamela J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Adjuvant; Aromatase inhibitors; Biology; Breast cancer; Intervention; Obesity

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN; AROMATASE INHIBITOR;

ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER SPECIFIC SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; INSULIN RESISTANCE; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TREATMENT INDICATION; BREAST NEOPLASMS; CHEMISTRY; COMPLICATION; DIET; FEMALE; LIFESTYLE; METABOLISM; MOTOR ACTIVITY; TREATMENT OUTCOME; WEIGHT LOSS PROGRAM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DIET; FEMALE; HUMANS; INSULIN RESISTANCE; LIFE STYLE; MOTOR ACTIVITY; OBESITY; TREATMENT OUTCOME; WEIGHT REDUCTION PROGRAMS;

EID: 84948719785     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.07.014     Document Type: Article

References (31)

1. Goodwin P.J. Obesity and endocrine therapy: host factors and breast cancer outcome. Breast 2013, 22(Suppl. 2):S44-S47.
2. Chan D.S., Vieira A.R., Aune D., et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014, 25:1901-1914.
3. Protani M., Coory M., Martin J.H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010, 123:627-635.
4. Niraula S., Ocana A., Ennis M., Goodwin P.J. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 2012, 134:769-781.
5. Sparano J.A., Wang M., Zhao F., et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012, 118:5937-5946.
6. Pajares B., Pollan M., Martin M., et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 2013, 15:R105.
7. Pan H., Gray R.R. Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. J Clin Oncol 2014, 32(15 Suppl.):503. on behalf of the Early Breast Cancer Trialists' Collaborative Group.
8. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013, 159:758-769.
9. Ewertz M., Gray K.P., Regan M.M., et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial. J Clin Oncol 2012, 30:3967-3975.
10. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
11. Gnant M., Mlineritsch B., Stoeger H., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641.
12. Seynaeve C., Hille E., Hasenburg A., et al. The impact of body mass index on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer patients: exploratory analysis from the TEAM study. Cancer Res 2010, 70(24 Suppl.):S2-S3. Abstr nr.
13. Gnant M., Pfeiler G., Stoger H., et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer 2013, 109:589-596.
14. Folkerd E.J., Dixon J.M., Renshaw L., et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 2012, 30:2977-2980.
15. Pfeiler G., Konigsberg R., Hadji P., et al. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. Br J Cancer 2013, 109:1522-1527.
16. Lonning P.E., Haynes B.P., Dowsett M. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur J Cancer 2014, 50:1055-1064.
17. Kyvernitakis I., Knoll D., Struck M., et al. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. J Cancer Res Clin Oncol 2014, 140:159-166.
18. Elliott K.M., Dent J., Stanczyk F.Z., et al. Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer. Br J Surg 2014, 101:939-948.
19. Goodwin P.J., Stambolic V. Impact of the obesity epidemic on cancer. Annu Rev Med 2015, 66:281-296.
20. Iyengar N.M., Hudis C.A., Dannenberg A.J. Obesity and cancer: local and systemic mechanisms. Annu Rev Med 2015, 66:297-309.
21. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011, 11:886-895.
22. Goodwin P.J., Ennis M., Pritchard K.I., et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 2012, 30:164-171.
23. Goodwin P.J., Segal R.J., Vallis M., et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol 2014, 32:2231-2239.
24. Chlebowski R.T., Blackburn G.L., Thomson C.A., et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006, 98:1767-1776.
25. Pierce J.P., Natarajan L., Caan B.J., et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007, 298:289-298.
26. Campbell K.L., Foster-Schubert K.E., Alfano C.M., et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol 2012, 30:2314-2326.
27. Mason C., Xiao L., Duggan C., et al. Effects of dietary weight loss and exercise on insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in postmenopausal women: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2013, 22:1457-1463.
28. Imayama I., Ulrich C.M., Alfano C.M., et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 2012, 72:2314-2326.
29. Abbenhardt C., McTiernan A., Alfano C.M., et al. Effects of individual and combined dietary weight loss and exercise interventions in postmenopausal women on adiponectin and leptin levels. J Intern Med 2013, 274:163-175.
30. Mason C., Foster-Schubert K.E., Imayama I., et al. Dietary weight loss and exercise effects on insulin resistance in postmenopausal women. Am J Prev Med 2011, 41:366-375.
31. Goodwin P.J., Parulekar W.R., Gelmon K.A., et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst 2015, 107(3). pii: djv006.